Room 218 B/219 B

Vascular and Blood Cells Responses to Novel Cardiovascular Biomaterials

The responses of vascular cells such as endothelial cells and smooth muscle cells to cardiovascular stents and vascular grafts are crucial for determining the success of these devices. The inhibition of smooth muscle cells is important for preventing neointimal hyperplasia while an enhanced endothelial cell growth can prevent late thrombosis.

Molecular Mechanisms Governing Protein-Surface and Cell-Surface Interactions

At a fundamental level, protein-surface and cell-surface interactions are governed by molecular interactions, which are still not well understood. This level of understanding is extremely important for the evolving field of molecular engineering, as well as for tissue engineering, regenerative medicine, drug-delivery systems and implantable medical devices. New and improved methods are needed and being developed to probe and understand these interactions.

Small Molecule Drug Delivery

Small molecule drug delivery is still a critical feature of many biomaterial innovations (e.g., tissue engineering, regenerative drug delivery, cardiovascular disease, etc.) The goal of this session is to highlight the advanced fabrication methods and designs in the regulation of small molecule release that can extend the limits of classical diffusion approaches.

Advances in Ophthalmic Biomaterials

Ophthalmic biomaterials arena is a rapidly growing area for advanced biomaterials research with wide-spread clinical applications. The demand for advanced ophthalmic care (non-elective procedures like cataract surgery, glaucoma surgery and age-related macular disease treatments) is growing at a rapid pace. For the 2015 SFB meeting, we would like to invite you to present on the progress of biomaterials research toward next-generation ophthalmic care. The scope of the session will encompass novel biomaterials technology and implant pathology in the ophthalmic arena.

Harnessing Biomaterials to Engineer the Adaptive Response for Immunity or Tolerance

Biomaterials are emerging as a powerful tool for harnessing adaptive immunity in the treatment of infectious disease, cancer, and autoimmunity, as well as to improve tissue engineering design and transplantation. This two-part symposium welcomes biomaterial-based strategies focused on directing adaptive immune response toward either immunity or toward tolerance.

Bio-Nanomaterials for Cancer Theranostic Treatment

The National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such asnew imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells.

Benchtop Models to Support Medical Device and Pharmaceutical Invention and Commercialization

FDA has recognized the ever-growing need to reduce costs in inventing and commercializing medical devices, pharmaceuticals, and drug delivery by using benchtop physiological models rather than animal models. Benchtop models can be used in invention (feasibility) as well as commercialization (verification and validation testing).

Vaccine Delivery Vehicles

Synthetic vaccines based on recombinant protein antigens or DNA-encoded antigens are a promising approach for combating infectious diseases, particularly in cases where whole pathogen vaccines are impracticable or unsafe. Synthetic vaccines based on tumor-associated antigens are also being pursued for cancer immunotherapy. The efficacy of protein and DNA vaccines can be greatly enhanced by the use of delivery vehicles that promote an antigen depot and/or uptake by antigen-presenting cells and co-deliver immunostimulatory adjuvant molecules such as cytokines or Toll-like receptor agonists.